Market opportunities in the IBD treatment sector include the rising demand for targeted therapies and biologics due to a deeper understanding of the disease, alongside the expansion of biosimilar ...

A toxin-secreting gut bacterium may fuel ulcerative colitis by killing protective immune cells that maintain intestinal homeostasis, according to a new study. The findings suggest potential for new ...

Interleukin-23 (IL-23) plays a pivotal role in the complex pathogenesis of both ulcerative colitis and Crohn's disease, making it a promising therapeutic target.1 Mirikizumab is a humanised IgG4 ...

Week held in Berlin, Germany, an informative session explored emerging approaches for the management of ulcerative colitis (UC), ranging from surgical interventions to updated treatment guidelines and ...

The following highlights spotlight the latest advances in gastroenterology, featuring studies and insights presented at this ...

IN his early 20s, Liam Robertson felt “indestructible”. He was super fit, always out with friends and couldn’t have been ...

Ulcerative colitis is a chronic, immune-mediated disorder of the colon, which is characterised by a relapsing–remitting course. Owing to the growing understanding of the immunopathogenesis of this ...

Therapeutic drug monitoring is associated with better treatment durability among children with inflammatory bowel diseases.

Rosnilimab was safe and well tolerated with similar adverse event rates vs. placeboObserved expected pharmacology, including ~90% depletion of ...

Get tips from experts for UC-related bloating relief. Learn to better manage symptoms with medication, diet changes, and lifestyle adjustments.

Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to assess bowel urgency across three measures — severity, frequency and stool deferral time — reflecting the spectrum of its ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy now. On October 7, Eli Lilly and Company announced new data from the LUCENT-3 Phase 3 open-label extension study demonstrating ...